Medigene expands platform technology with patent for identification of CD4+ T cell antigens
Provides a new source for potential TCR candidates
26-Jul-2016 -
Medigene AG, a clinical stage immune-oncology company focusing on the development of T cell immuno-therapies for the treatment of cancer, announces the grant of US patent US9,341,617B2. The patent, with an expected life-span until 2030, claims a method for the identification of antigens ...
antigens
cancer vaccines
patents
+1